

Special Issue

Flaviviruses: Immunity and Vaccine Development

Message from the Guest Editors

The COVID pandemic is a reminder of how vulnerable the world's population is to zoonotic RNA viruses of medical concern. Among the viruses most likely to emerge and re-emerge is the arthropod-borne flavivirus family, which includes dangerous pathogens that currently infect hundreds of millions of people per year. The dengue virus (DENV), West Nile (WNV), yellow fever (YFV), Zika (ZIKV), Japanese encephalitis virus (JEV), tick-borne encephalitis virus (TBEV), and Usutu virus (USUV) are well-known members of the flavivirus family. They are responsible for a wide range of potentially serious visceral, neurotropic, and congenital diseases, as well as fetal death. The purpose of this Special Issue, titled "Flavivirus: Immunity and Vaccine Development", is to present the latest research results, hypothesis, and points of view on the field of flaviviruses–host interactions and conception of vaccine strategies. It is likely to be of interest to a wide range of translational researchers, virologists, cell and molecular biologists, physicians, etc.

Dr. Pascale Krejbich

Guest Editors

Dr. Wildriss Viranaicken

PIMIT, Processus Infectieux en Milieu Insulaire Tropical, Université de La Réunion, INSERM UMR 1187, CNRS 9192, IRD 249, Plateforme CYROI, 97490 Sainte-Clotilde, Ile de La Réunion, France

Dr. Pascale Krejbich-Trotot

CYROI Technological Platform, Mixed Unit for Infectious Processes in Tropical Island Environments, University of Réunion, Réunion, France

Deadline for manuscript submissions

closed (31 December 2023)



Vaccines

an Open Access Journal
by MDPI

Impact Factor 3.4
CiteScore 9.9
Indexed in PubMed



mdpi.com/si/111271

Vaccines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
vaccines@mdpi.com

[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)





Vaccines

an Open Access Journal
by MDPI

Impact Factor 3.4
CiteScore 9.9
Indexed in PubMed



[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)



About the Journal

Message from the Editor-in-Chief

Vaccines (ISSN 2076-393X) has had a 6-year history of publishing peer-reviewed state of the art research that advances the knowledge of immunology in human disease protection. Immunotherapeutics, prophylactic vaccines, immunomodulators, adjuvants and the global differences in regulatory affairs are some of the highlights of the research published that have shaped global health. Our open access policy allows all researchers and interested parties to immediately scrutinize the rigorous evidence our publications have to offer. We are proud to present the work and perspectives of many to contribute to future decisions concerning human health.

Editor-in-Chief

Prof. Dr. Ralph A. Tripp

Department of Infectious Diseases, College of Veterinary Medicine,
University of Georgia, Athens, GA 30602-7387, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPIus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Medicine, Research and Experimental) /
CiteScore - Q1 (Pharmacology (medical))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 19.6 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the first half of 2025).